Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516117 | 0.87 | ADORA3 (0.34) | ADORA3ADORA2AADORA2B | |
| Trifluoroacetic Acid SCHEMBL3514923 | 0.80 | PSMB8 (0.32) | ADORA3ADORA2AADORA2B | |
| SCHEMBL5554652 | 0.74 | — | — | |
| SCHEMBL21694902 | 0.74 | DNMT1 (0.33) | — | |
| SCHEMBL45123 | 0.74 | KDM4E (0.46) | KDM4E | |
| SCHEMBL8142065 | 0.73 | RAB9A (0.43) | KDM4E | |
| Hydrochloric Acid SCHEMBL44961 | 0.72 | KDM4E (0.44) | KDM4E | |
| SCHEMBL1441637 | 0.71 | KMT2A (0.44) | KDM4E | |
| SCHEMBL27456186 | 0.71 | KDM4E (0.32) | KDM4E | |
| SCHEMBL10029753 | 0.71 | CAPN1 (0.39) | ADORA3ADORA2AADORA2BMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | ADORA3 2706/4885ADORA2A 1784/4885ADORA2B 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.